Connection
William Robinson to Pyrimidines
This is a "connection" page, showing publications William Robinson has written about Pyrimidines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.463 |
|
|
|
-
Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate. J Cutan Pathol. 2008 Feb; 35(2):197-202.
Score: 0.226
-
Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. J Cutan Pathol. 2007 Apr; 34(4):324-9.
Score: 0.213
-
Feun LG, Gonzalez R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar; 9(3):464-7.
Score: 0.017
-
Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. Am J Clin Oncol. 1995 Dec; 18(6):488-90.
Score: 0.006